TY - JOUR

T1 - Secretion, blood levels and cutaneous expression of TL1A in psoriasis patients

AU - Pedersen, Anders Elm

AU - Schmidt, Esben Gjerløff Wedebye

AU - Sørensen, Jesper Freddie

AU - Faber, Carsten

AU - Nielsen, Boye Schnack

AU - Holmstrøm, Kim

AU - Omland, Silje Haukali

AU - Tougaard, Peter

AU - Skov, Søren

AU - Bang, Bo

N1 - © 2015 APMIS. Published by John Wiley & Sons Ltd.

PY - 2015/7

Y1 - 2015/7

N2 - TL1A is a TNF-like cytokine which has been shown to co-stimulate TH1 and TH17 responses during chronic inflammation. The expression of this novel cytokine has been investigated in inflammatory disorders like rheumatoid arthritis and inflammatory bowel disease, but little is known about expression and induction in psoriasis. Indeed, the pathogenesis in psoriasis is still not fully understood and it is speculated that cytokines other than TNF-α are important in subsets of patients. Also, for patients with severe disease that are treated with systemic anti-TNF-α blockade, novel candidates to be used as disease and response biomarkers are of high interest. Here, we demonstrate TL1A expression in biopsies from psoriatic lesions. Also, we investigated spontaneous and induced TL1A secretion from PBMCs and blood levels from a cohort of psoriasis patients. Here, increased spontaneous secretion from PBMCs was observed as compared to healthy controls and a small subset of patients had highly elevated TL1A in the blood. Interestingly, activation of PBMCs with various cytokines showed a decreased sensitivity for TL1A activation in psoriasis patients compared to healthy controls.TL1A levels in blood and biopsies could not be correlated with disease activity with this patient cohort. Thus, additional large-scale studies are warranted to investigate TL1A as a biomarker.

AB - TL1A is a TNF-like cytokine which has been shown to co-stimulate TH1 and TH17 responses during chronic inflammation. The expression of this novel cytokine has been investigated in inflammatory disorders like rheumatoid arthritis and inflammatory bowel disease, but little is known about expression and induction in psoriasis. Indeed, the pathogenesis in psoriasis is still not fully understood and it is speculated that cytokines other than TNF-α are important in subsets of patients. Also, for patients with severe disease that are treated with systemic anti-TNF-α blockade, novel candidates to be used as disease and response biomarkers are of high interest. Here, we demonstrate TL1A expression in biopsies from psoriatic lesions. Also, we investigated spontaneous and induced TL1A secretion from PBMCs and blood levels from a cohort of psoriasis patients. Here, increased spontaneous secretion from PBMCs was observed as compared to healthy controls and a small subset of patients had highly elevated TL1A in the blood. Interestingly, activation of PBMCs with various cytokines showed a decreased sensitivity for TL1A activation in psoriasis patients compared to healthy controls.TL1A levels in blood and biopsies could not be correlated with disease activity with this patient cohort. Thus, additional large-scale studies are warranted to investigate TL1A as a biomarker.

KW - Adult

KW - Aged

KW - Biological Markers

KW - Case-Control Studies

KW - Cytokines

KW - Female

KW - Healthy Volunteers

KW - Humans

KW - Immunohistochemistry

KW - Leukocytes, Mononuclear

KW - Male

KW - Middle Aged

KW - Pilot Projects

KW - Psoriasis

KW - Skin

KW - Tumor Necrosis Factor Ligand Superfamily Member 15

KW - Young Adult

U2 - 10.1111/apm.12385

DO - 10.1111/apm.12385

M3 - Journal article

C2 - 25908025

VL - 123

SP - 547

EP - 555

JO - A P M I S. Acta Pathologica, Microbiologica et Immunologica Scandinavica

JF - A P M I S. Acta Pathologica, Microbiologica et Immunologica Scandinavica

SN - 0903-4641

IS - 7

ER -